TY - JOUR
AR - ACO-2019-3-103
TI - KRAS Mutation as Predictor Factor in Locally Advanced Rectal Cancer
AU -  Flamarique , Sonia
AU - Asin , Gemma
AU - Campo, M
AU - Fernando, Arias
AU - Guerrero, David
AU - Rodriguez, M
JO - Annals of Clinical Oncology
PY - 2019
DA - Sat 24, Aug 2019
SN - 2674-3248
DO - http://dx.doi.org/10.31487/j.ACO.2019.03.03
UR - https://www.sciencerepository.org/kras-mutation-as-predictor-factor-in-locally-advanced-rectal-cancer_ACO-2019-3-103 
KW - Rectal cancer, neoadjuvant treatment, KRAS
AB - Introduction: Standard treatment of locally advanced rectal cancer (LARC) includes neoadjuvant chemoradiotherapy followed by total mesorectal excision (TME). The role of KRAS as a biomarker in rectal cancer
remains equivocal. We evaluate the Tumor Regression Grade (TRG), Relapse-Free Survival (RFS) and
Overall Survival (OS) according to the KRAS oncogene status in LARC
Material and Method: We evaluated the KRAS status in 23 patients with LARC. Tumor DNA was
obtained from pretreatment biopsy tissues.
Results: KRAS mutation was found in 30,4% of the patients. TRG (1-2) after CRT were 56,2% and 42,8%,
for wild-type and mutant KRAS groups (p= NS). After a median follow-up of 31 months, there was no
difference in RFS (47,7 vs 23,3 months) or OS (51,5 vs 30 months) between wild-type and mutant-type
KRAS groups, respectively.
Conclusions: Although KRAS status seems to have slightly better prognosis in LARC, it does not reach
significant results (probably due to insufficient sample) in TRG, RFS or OS.